Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 15 wrz 2022 · A commonly accepted paradigm (based on Virchow’s triad of thrombogenesis) posits the pathogenesis of LV thrombus as occurring as a result of the interplay of 3 factors: (1) stasis attributable to reduced ventricular function, (2) endocardial injury, and (3) inflammation/hypercoagulability (Figure 1).

    • View EPUB

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Linda S. Williams

      Many diseases with specific indications for specific...

    • PDF/Epub

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Trial

      Background—The Randomized Evaluation of Long-term...

  2. 23 wrz 2022 · If OAC is initiated, a treatment duration might be 13 months, depending on bleeding risk. On the basis of reasonable data and evidence, post-MI patients with LV thrombus should be treated with OAC, typically for a duration of 3 months.

  3. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. Your access to the latest cardiovascular news, science, tools and resources.

  4. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies. AHA Guideline and Statements Hub content for Management of Patients at Risk for and with Left Ventricular Thrombus.

  5. Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).

  6. Introduction Left ventricular thrombus (LVT) is a frequent complication of left ventricular systolic dysfunction (1). Incidence following acute myocardial infarction is estimated at 13–20% and up to 15% in with non-ischaemic cardiomyopathy (2, 3). Once diagnosed, guidelines recommend anticoagulation with vitamin K antagonists (VKA) to reduce ...

  7. Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.

  1. Ludzie szukają również